Oligo-heteropolysaccharides having a heparin-like activity method for their preparation and pharmaceutical compositions based thereon

Claim 1

A method of increasing the antithrombotic activity of mammalian blood relative to the anticoagulant activity comprising administering to a mammal in need of treatment for thrombosis, an oligoheteropolysaccharide comprising depolymerized heparin containing sulfate groups in the quantity and in the positions characteristic of heparin wherein said oligoheteropolysaccharide has the following physico chemical properties: (A) average molecular weight (determined with the Somogy method in comparison with commercial heparin) from 2600 to 5500 daltons; (B) hexosamines after hydrolysis (reaction with p-dimethyl-amino benzaldehyde): 28%±2%; (C) uronic acids after hydrolysis (reaction with carbazol): 31%±4%; (D) organic SO 4 = after hydrolysis (titration with naphtharsone): 30%±4%; (E) molar ratios of uronic acids/hexosamines/SO 4 = =1/1/2; (F) specific rotatory power of the aqueous solution [α] D 20 =+40°-+50°; (G) electrophoresis on cellulose acetate (pyridine/acetic acid/water (1:10:299)) pH 4.5 and development with toluidine blue=a single band with anodic mobility U=2.1×10 -4 cm 2 v -1 sec -1 ; (H) powder of ivory color, amorphous and slightly hygroscopic; (I) aqueous solution clear or slightly opalescent; and (J) pH of 5% aqueous solution: 7-8.

Claim 2

A method of increasing the antithrombotic activity of mammalian blood relative to the anticoagulant activity comprising administering to a mammal in need of treatment for thrombosis, an oligoheteropolysaccharide comprising depolymerized heparin containing sulfate groups in the quantity and in the positions characteristic of heparin wherein said oligoheteropolysaccharide has the following physico chemical properties: (A) average molecular weight (determined with the Somogy method in comparison with commercial heparin) from 2600 to 5500 daltons; (B) hexosamines after hydrolysis (reaction with p-dimethyl-amino benzaldehyde): 28%±2%; (C) uronic acids after hydrolysis (reaction with carbazol): 31%±4%; (D) organic SO 4 = after hydrolysis (titration with naphtharsone): 30%±4%; (E) molar ratios of uronic acids/hexosamines/SO 4 = =1/1/2; (F) specific rotatory power of the aqueous solution [α] D 20 =+40°-+50°; (G) electrophoresis on cellulose acetate (pyridine/acetic acid/water (1:10:299)) pH 4.5 and development with toluidine blue=a single band with anodic mobility U=2.1×10 -4 cm 2 v -1 sec -1 ; (H) powder of ivory color, amorphous and slightly hygroscopic; (I) aqueous solution clear or slightly opalescent; and (J) pH of 5% aqueous solution: 7-8.

Claim 3

A method of increasing the antithrombotic activity of mallalian blood relative to the anticoagulant activity comprising administering to a mammal in need of treatment for thrombosis an oligoheteropolysaccharide comprising depolymerized heparin having an average molecular weight of about 2600 to about 5500 daltons determined by the Somogy method in comparison with commercial heparin and having sulfate groups in the quantity and in the positions characteristic of heparin, which oligoheteropolysaccharide displays greater antithrombotic activity than anticoagulant activity.

Claim 4

A method of increasing the antithrombotic activity of mallalian blood relative to the anticoagulant activity comprising administering to a mammal in need of treatment for thrombosis an oligoheteropolysaccharide comprising depolymerized heparin having an average molecular weight of about 2600 to about 5500 daltons determined by the Somogy method in comparison with commercial heparin and having sulfate groups in the quantity and in the positions characteristic of heparin, which oligoheteropolysaccharide displays greater antithrombotic activity than anticoagulant activity.

Claim 5

A method of increasing the antithrombotic activity of mammalian blood relative to the anticoagulant activity comprising administering to a mammal an effective amount of a therapeutical composition, for the prevention of thrombosis, characterized in that it contains as the active ingredient the oligoheteropolysaccharide as described in claims 1 or 2.